Ipsen: first patient treated for study on IPN01087

(CercleFinance.com) - Ipsen and 3BP have announced that a first patient has been treated with a radionuclide of a new therapeutic class, 177Lu-IPN01087 (formerly known as 3BP-227), in a phase I/II study.


"IPN01087 is a compound that targets cancer cells in patients with advanced solid tumors which express the Neurotensin Receptor Subtype 1 (NTSR1)," the pharmaceutical laboratories said.

The main objective is to assess tolerance and efficiency, as well as the optimal dose of treatment by the system of the radio-isotope administered systemically to treat patients with solid tumours, such as colorectal cancer or Ewing sarcoma.



Copyright (c) 2018 CercleFinance.com. All rights reserved.